companies developing glp-1 drugs Solving the Unmet Needs in Obesity Treatment | Obesity Pulse GLP-1 Safety Check - National

Diabetologia 1998;41:41623

moderate renal impairment (eGFR 30-45 ml/min) has been observed to increase plasma levels of sitagliptin 2-fold, and severe renal impairment can increase plasma levels 4-fold

Wonki K, Kim JA, Lee SH, Bae S, Choi IY, Kim YH

Many providers lock you into semaglutide only DirectMeds gives you the option to start with either semaglutide or tirzepatide based on your provider's recommendation

Allergy Awareness: We conduct thorough evaluations to identify any hypersensitivity to semaglutide or its components, ensuring safe administration and avoiding allergic reactions

Data analysed by one-way ANOVA, multiple comparison, Bonferroni post hoc test ( c , e , g , l , n , p , v , x and z ) and two-way repeated measures ANOVA to assess main effects of treatment ( i , j , q , s and t )